Company / Operating Cash Flow per Share
Ligand Pharmaceuticals, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$2.58
FY2025
5-year range
$2.58 / $8.22
FY2021-FY2025
Trend
-53.3%
vs FY2024
Sector context
#37 of 212
Health Care
What the data says
Ligand Pharmaceuticals, Inc.'s operating cash flow per share of $2.58 is higher than 83% of companies in the Health Care sector (FY2025). Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-1.41 in FY2019 to $9.18 in FY2018.
Based on SEC 10-K filings.
2.58 in FY2025 with a 5-year CAGR of -4.5%. Top quartile in the Health Care sector.
Declined from $2.92 to $2.58 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -32.0%
- 5-Year CAGR
- -4.5%
- 10-Year CAGR
- -
Sector benchmark
+117.5% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 53.3% year-over-year.
- Ranks #37 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2018.
- Lowest operating cash flow per share in the period was in FY2019.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.58 | -53.3% |
| FY2024 | $5.53 | +89.0% |
| FY2023 | $2.92 | -64.4% |
| FY2022 | $8.22 | +67.8% |
| FY2021 | $4.90 | +51.0% |
| FY2020 | $3.24 | +329.7% |
| FY2019 | -$1.41 | -115.4% |
| FY2018 | $9.18 | +116.6% |
| FY2017 | $4.24 | +39.1% |
| FY2016 | $3.04 | +42.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026